Stéphane Bancel, Moderna CEO (Charles Krupa/AP Images)

'The ur­gency is in­creas­ing': Mod­er­na spot­lights vac­cine, or­phan drug pro­grams, as it plots growth be­yond Covid

At its R&D day two years ago, Mod­er­na was still anx­ious­ly await­ing Phase III da­ta on its Covid-19 vac­cine. In a pre­view, CEO Stéphane Ban­cel talked about the next 12 months be­ing “the biggest in­flec­tion point ever” if the shot got launched — as he laid out his new vi­sion for a high-fly­ing biotech vault­ed three to four years ahead by the pan­dem­ic.

“We have 20 drugs in clin­i­cal de­vel­op­ment to­day,” Ban­cel told End­points News at the time. “Could we, in 18 months, 24 months from now have 40? 50? I think it’s pos­si­ble.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.